language_icon
EN
HI

Biocon Share price

BIOCON

417.6

15.15 (3.76%)
NSE
BSE
Last updated on 13 May, 2026 | 15:59 IST
Today's High

420.25

Today's Low

402.85

52 Week Low

317.90

52 Week High

424.95

Zero AMC

Free Demat with Zero AMC*

Open a Free Demat Account
+ Free 1st Year AMC

Biocon Chart

Biocon Share Key Metrics

Volume
1.14 CR
Market Cap
67689.11 CR
LTQ@LTP
1@417.60
ATP
414.93
Var Margin
15.5 %
Circuit Range
362.25-442.65
Delivery %
31.9 %
Value
474.89 CR
ASM/GSM
No
Market Lot
1

Summary

Biocon share price stands at ₹417.6 at 13 May, 2026 | 15:59. The stock Biocon intraday movement has stayed between ₹402.85 and ₹420.25, while on a 52-week basis it has fluctuated from ₹317.90 to ₹424.95.
In terms of trading activity, Biocon has recorded a volume of 11445147 shares. The Biocon has a market cap of ₹1620907773. The stock’s Average Traded Price (ATP) stands at ₹41493, while the Last Traded Quantity at Last Traded Price (LTQ@LTP) is 1, 41760.
The Biocon operates within a circuit range of ₹362.25-442.65 – ₹362.25-442.65, with a Value of ₹474.89 CR. The Delivery Percentage for the day is 31.9%. Additionally, Biocon currently falls under the No framework, and trades with a market lot size of 1.

Biocon Fundamentals

View More
P/E Ratio

169.05

P/B Ratio

1.92

Div. Yield

0.12

Sector P/E

67.07

Sector P/B

3.49

Sec. Div. Yield

0.57

Biocon Resistance and Support

Pivot 400.43

Resistance

First Resistance

408.61

Second Resistance

414.78

Third Resistance

422.96

Support

First Support

394.26

Second Support

386.08

Third Support

379.91

Biocon Futures & Options

417.6

15.15 (3.76%)

link_white_icon

Biocon Option Chain

View Price, OI, Greeks & More...
View All

26MAY26

418.25

13.85 (3.42%)

30JUN26

420.10

13.45 (3.31%)

28JUL26

421.50

14.35 (3.52%)

BIOCON|26MAY26 CE 415.00

11.60

5.7 (96.61%)

BIOCON|26MAY26 PE 420.00

10.75

-9.1 (-45.84%)

Biocon Shareholding Pattern

View More
  • 2016-17
  • 2018-19
  • 2019-20
  • 2020-21
  • 2021-22
  • 2022-23
  • 2023-24
  • 2024-25
  • 2025-26
  • 2026-27
Total Promoters
Segment
Percent

Total Promoters

60.64%

Mutual Fund

8.58%

Insurance

6.43%

Foreign Institutional Investors

5.66%

Domestic Institutional Investors

0.35%

Retail

18.34%

Others

0%

Total Promoters
MAR '24
60.64%
JUN '24
60.64%
SEP '24
60.64%
DEC '24
60.64%

Biocon Corporate Actions

DateAgenda
2026-05-07Audited Results & Final Dividend
2026-02-12Quarterly Results
2025-11-11Quarterly Results
2025-10-01Redemption (Part) of NCD
2025-08-07Quarterly Results
2025-05-08Audited Results & Final Dividend
2025-04-23Others
2025-04-04To consider Fund Raising
2025-01-30Quarterly Results & Others
2025-01-27Others

Biocon News

Biocon shares gain after Health Canada approval for injection used in treating bloodstream infections

Biocon Pharma Limited, a subsidiary of Biocon, has received approval from Health Canada for its Micafungin for Injection, USP (50 mg and 100 mg). This antifungal medication is indicated for treating various fungal infections in adults and pediatric patients, and for prophylaxis in hematopoietic stem cell transplant patients. This regulatory clearance is expected to enhance Biocon's integrated biosimilars and generics portfolio and expand its presence in the Canadian market.
May 11 2026 10:05:00

Kiran Mazumdar-Shaw names niece Claire as successor, targets semaglutide push from FY28; debt cut to $1.1 billion

Biocon's Executive Chairperson, Kiran Mazumdar-Shaw, has named her niece Claire Mazumdar as her successor, outlining a five-year transition plan. The company also announced plans to target peak revenue of $500 million to $700 million from Semaglutide by FY30, with a push starting from FY28, and aims to reduce its current debt of $1.8 billion to $1.1 billion by FY28.
May 11 2026 09:05:00

Biocon Ltd - 532523 - Shareholder Meeting / Postal Ballot-Notice of Postal Ballot

Biocon has initiated a Postal Ballot for shareholder approval on several key resolutions. These include revisions to Executive Chairperson's remuneration, the appointment of Shreehas Pradeep Tambe as CEO & MD, and a preferential issue of equity shares to acquire the remaining minority stake in Biocon Biologics, making it a wholly-owned subsidiary for strategic integration.
May 09 2026 01:05:00

Biocon Ltd - 532523 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome

Biocon announced the availability of the audio and video recording of its Q4 FY26 Earnings Call, held on May 08, 2026. Investors can access the recording via links provided on the company's website.
May 08 2026 21:05:00

Biocon Q4 Results: Net profit down 57% at Rs 198.6 crore

Biocon Ltd. reported a significant decline in its Q4 FY26 net profit, falling 56.8% to ₹198.6 crore, primarily due to an ₹80.4 crore exceptional item. Despite the profit drop, the company's consolidated revenue for the quarter increased to ₹4516.6 crore. For the full fiscal year 2026, net profit also decreased to ₹368.8 crore, while revenue grew to ₹16927 crore.
May 08 2026 10:05:00

Biocon Ltd - 532523 - Announcement under Regulation 30 (LODR)-Monitoring Agency Report

Biocon's monitoring agency report confirms full utilization of over Rs.8,650 crore QIP funds as per stated objects for Q4 FY26. The funds were primarily used for acquisitions and debt repayment across two QIPs.
May 08 2026 00:05:00

Biocon Ltd - 532523 - Outcome Of Board Meeting_Change In Long Term Incentive Plan

Biocon's Board approved the acquisition of the remaining ~2% equity shares in its material subsidiary, Biocon Biologics Limited (BBL). This acquisition, valued at Rs.330.73 crores through a preferential issue of Biocon shares, aims for full integration and operational synergies, making BBL a nearly 99.99% owned subsidiary.
May 07 2026 23:05:00

Biocon Ltd - 532523 - Announcement under Regulation 30 (LODR)-Issue of Securities

Biocon's Board approved a preferential issue of 87.92 lakh equity shares at Rs. 376.16 per share, totaling Rs. 330.73 crore. This issuance is to acquire the remaining ~2% stake in its material subsidiary, Biocon Biologics Limited (BBL), aiming for full integration and simplified corporate structure.
May 07 2026 23:05:00

Biocon Ltd - 532523 - Announcement under Regulation 30 (LODR)-Acquisition

Biocon plans to acquire the remaining ~2% equity stake in its material subsidiary, Biocon Biologics. The acquisition, valued at Rs. 330.73 crores through a preferential issue of Biocon shares, will increase its ownership to approximately 99.99%, aiming to fully integrate the biosimilars business.
May 07 2026 23:05:00

Biocon Ltd - 532523 - Outcome Of Board Meeting_Completion Of Tenure Of Statutory Auditors

Biocon's Board approved the acquisition of the remaining ~2% equity shares in its material subsidiary, Biocon Biologics Limited (BBL). This acquisition, valued at Rs.330.73 crores through a preferential issue of Biocon shares, aims for full integration and operational synergies, making BBL a nearly 99.99% owned subsidiary.
May 07 2026 23:05:00
Read More

About Biocon

NSE : 11373  
BSE : 532523  
ISIN : INE376G01013  

HISTORY AND CERTAIN CORPORATE MATTERSOur Company was incorporated as Biocon India Private Limited onNovember 29 1978 under the Companies Act. The word `Private' wasdeleted from our name under the provisions of Section 43A(2) of theCompanies Act with effect from July 1 1995. Thereafter our Company wasconverted to a private limited company under the provisions of Section43(2A) of the Companies Act with effect from December 21 2000. It wasreconverted into a public limited company on June 18 2001. The name ofour Company was changed from Biocon India Limited to Biocon Limited anda fresh certificate of incorporation consequent on change of name wasissued by the RoC on November 19 2003.Our Corporate StructureOur existing corporate structure is as under:Biocon LimitedClinigene International PrivateLimited (100.00%)Biocon Biopharmaceuticals PrivateLimited (51.00%)Syngene International PrivateLimited (99.99%)Interest of Promoters Directors and Key Managerial PersonnelExcept as stated in ?Related Party Transactions? on page 84 of this RedHerring Prospectus and to the extent of shareholding in our Companythe Promoters do not have any other interest in our business.Our Promoters have significant rights in our Company under the terms ofour Articles of Association. For additional information please referto the section entitled ?Main Provisions of Articles of Association ofBiocon Limited? on page 168 of this Red Herring Prospectus.Except to the extent of their compensation and to the extent of ESOPif any as mentioned on page 165 of this Red Herring Prospectus andtheir shareholding or shareholding of companies they represent theDirectors other than Promoter Directors do not have any otherinterest in our Company. Our Director Mr. John Shaw is the husband ofour Chairman & Managing Director Ms. Kiran Mazumdar-Shaw. OurDirector Prof. Ravi Mazumdar is the brother of our Chairman & ManagingDirector Ms. Kiran Mazumdar-Shaw. Our alternate Director Prof.Catherine Rosenberg is the sister-in-law of our Chairman & ManagingDirector Ms. Kiran Mazumdar-Shaw.The key managerial personnel of our Company do not have any interest inour Company other than to the extent of the remuneration or benefits towhich they are entitled to as per their terms of appointment andreimbursement of expenses incurred by them during the ordinary courseof business and to the extent of the Equity Shares held by them in theCompany if any and options granted to them under the ESOP.

Read More

Biocon Management

NamePosition
Kiran Mazumdar-ShawChairperson
Ravi Rasendra MazumdarNon Independent & Non Executive Director
View More

Biocon FAQs

The Buying Price of Biocon share is 417.6 For live prices and instant trading, you can log in to your Choice trading account or open a Free Demat account with Choice.

To buy Biocon stocks, log in to your Choice trading account. If you don’t have one, open a Choice Demat account. Then, add funds, search for Biocon, choose your preferred order type, and place the trade.

The Price-to-earnings (P/E) ratio of Biocon shares is 169.05. You can compare it with the sector average for relative valuation.

The Price to Book (P/B) ratio Biocon shares is 1.92. Useful to assess the stock's value relative to its book value.

To assess Biocon’s valuation compare Sector P/E, P/B which are 67.07 & 3.49 with sector averages, along with growth rates and financial metrics.

The Market Cap of Biocon is 67689.11 CR. It indicates the company's size category and trading liquidity.

The 52 week high and low prices of Biocon share price is 424.95 & 317.90. They indicate price extremes, trading ranges, volatility measures, potential support/resistance, and price momentum.

Biocon belongs to the Healthcare sector.

Invest with Zero-Cost Demat Account

Zero AMC for First Year
Free Research Calls
₹ 0 Trade & Call Fee
Zero-Cost